Yeah, there are a lot of small/nano biopharmas, Verastem, Scynexis et al. that are doing much better financially with far less exciting drugs or products, with a much better share structure and a more balanced strategy of financing (selling tax loss credits, regular institutional investors, institutional investors who buy above market prices, raising a lot of cash at once when the price is high etc.). So let's not pretend that the CYDY situation is normal. But thanks for your "edification".